These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 26551044)
41. A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy. Morton CA; Dominicus R; Radny P; Dirschka T; Hauschild A; Reinhold U; Aschoff R; Ulrich M; Keohane S; Ekanayake-Bohlig S; Ibbotson S; Ostendorf R; Berking C; Gröne D; Schulze HJ; Ockenfels HM; Jasnoch V; Kurzen H; Sebastian M; Stege H; Staubach P; Gupta G; Hübinger F; Ziabreva I; Schmitz B; Gertzmann A; Lübbert H; Szeimies RM Br J Dermatol; 2018 Aug; 179(2):309-319. PubMed ID: 29432644 [TBL] [Abstract][Full Text] [Related]
42. Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma. Cosgarea R; Susan M; Crisan M; Senila S J Eur Acad Dermatol Venereol; 2013 Aug; 27(8):980-4. PubMed ID: 22738399 [TBL] [Abstract][Full Text] [Related]
43. Fractionated aminolevulinic acid-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer. de Haas ER; de Vijlder HC; Sterenborg HJ; Neumann HA; Robinson DJ J Eur Acad Dermatol Venereol; 2008 Apr; 22(4):426-30. PubMed ID: 18031503 [TBL] [Abstract][Full Text] [Related]
44. Reflectance confocal microscopy allows in vivo real-time noninvasive assessment of the outcome of methyl aminolaevulinate photodynamic therapy of basal cell carcinoma. Venturini M; Sala R; Gonzàlez S; Calzavara-Pinton PG Br J Dermatol; 2013 Jan; 168(1):99-105. PubMed ID: 23013443 [TBL] [Abstract][Full Text] [Related]
45. Methyl aminolevulinate photodynamic therapy after partial debulking in the treatment of superficial and nodular basal cell carcinoma: 3-years follow-up. Gómez C; Cobos P; Alberdi E Photodiagnosis Photodyn Ther; 2021 Mar; 33():102176. PubMed ID: 33429099 [TBL] [Abstract][Full Text] [Related]
46. Urticaria after methyl aminolevulinate photodynamic therapy in a patient with nevoid basal cell carcinoma syndrome. Wolfe CM; Green WH; Hatfield HK; Cognetta AB J Drugs Dermatol; 2012 Nov; 11(11):1364-5. PubMed ID: 23135091 [TBL] [Abstract][Full Text] [Related]
47. Giant and large basal cell carcinoma treated with topical photodynamic therapy. Eibenschutz L; Marenda S; Buccini P; De Simone P; Ferrari A; Mariani G; Silipo V; Catricalà C Eur J Dermatol; 2008; 18(6):663-6. PubMed ID: 18955200 [TBL] [Abstract][Full Text] [Related]
48. Photodynamic therapy in the management of basal cell carcinoma: Retrospective evaluation of outcome. Jerjes W; Hamdoon Z; Hopper C Photodiagnosis Photodyn Ther; 2017 Sep; 19():22-27. PubMed ID: 28442314 [TBL] [Abstract][Full Text] [Related]
49. Topical methyl aminolevulinate. Siddiqui MA; Perry CM; Scott LJ Am J Clin Dermatol; 2004; 5(2):127-37; discussion 138-40. PubMed ID: 15109276 [TBL] [Abstract][Full Text] [Related]
50. The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome. Tyrrell JS; Campbell SM; Curnow A Lasers Surg Med; 2010 Sep; 42(7):613-9. PubMed ID: 20806386 [TBL] [Abstract][Full Text] [Related]